Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sanofi - American Depositary Shares (NQ:SNY)

48.74 +0.39 (+0.81%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 987,992
Open 48.77
Bid (Size) 48.00 (400)
Ask (Size) 49.00 (700)
Prev. Close 48.35
Today's Range 48.66 - 48.95
52wk Range 44.62 - 60.12
Shares Outstanding 1,250,690,553
Dividend Yield 4.54%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Biopharma’s Year-End Rollercoaster: Mereo Plummets 90% as BioMarin Seals $4.8 Billion Amicus Deal
The biopharmaceutical sector witnessed a dramatic surge in volatility today, December 29, 2025, as the industry careened toward the end of its strongest year in two decades. In a day defined by extreme... 
Via MarketMinute
Topics ETFs Intellectual Property
News headline image
The Dynavax Turnaround: From Clinical Setbacks to a $2.2 Billion Exit
As of December 26, 2025, the biotechnology landscape is processing one of the most significant mid-cap acquisitions of the year. Dynavax Technologies Corporation (NASDAQ: DVAX) has transitioned from a... 
Via PredictStreet

Performance

YTD
+1.1%
+1.1%
1 Month
-2.4%
-2.4%
3 Month
+6.8%
+6.8%
6 Month
+0.9%
+0.9%
1 Year
+1.1%
+1.1%

More News

Read More
News headline image
The Great Vaccine Consolidation: Sanofi’s $2.2 Billion Strategic Bet on Dynavax Technologies
Via PredictStreet
Topics Economy Intellectual Property
News headline image
The Vaccine Vanguard: Inside Sanofi’s $2.2 Billion Strategic Bet on Dynavax
Via PredictStreet
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Why Dynavax Stock Soared Today ↗
Via The Motley Fool
News headline image
Sanofi’s $2.2 Billion Strategic Pivot: Deconstructing the Dynavax Acquisition and the Future of Specialty Medicine
Via PredictStreet
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Dynavax Technologies: Analyzing the 39% Surge and Sanofi Acquisition
Via PredictStreet
Topics Economy
News headline image
Sanofi Acquires Dynavax in $2.2 Billion Christmas Eve Deal, Sending Shares Soaring
Via MarketMinute
Topics Intellectual Property
News headline image
Why Did Dynavax Stock Surge 38% In Premarket Today? ↗
Via Stocktwits
Fitch Sees Stable 2026 Outlook For Global Pharma — But Warns Trump Drug Pricing Push Poses Profit Risk ↗
Via Stocktwits
Topics Government
News headline image
Dupixent® (dupilumab) Approved in Japan for Children Aged 6 to 11 Years with Bronchial Asthma
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
The Biotech Renaissance: Innovation and M&A Frenzy Spark a Historic Year-End Rally
Via MarketMinute
Topics ETFs Economy Intellectual Property
News headline image
Trump Strikes New Drug-Price Deals With Roche, Novartis, Merck And Other Pharma Giants ↗
Via Stocktwits
Topics Government World Trade
News headline image
Is Alnylam Pharmaceuticals a Millionaire Maker? ↗
Via The Motley Fool
News headline image
Moderna, BioNTech Slammed After FDA Links Covid Shots To 10 Deaths ↗
Via Investor's Business Daily
Topics Death
News headline image
Should You Buy This Biotech Stock That Just Gained 5% in 1 Day? ↗
Via The Motley Fool
News headline image
Sanofi Stock Drops After Confirming Raid, Tax Fraud Investigation ↗
Via Investor's Business Daily
Topics Fraud
News headline image
Dupixent® (dupilumab) Approved as the First Targeted Medicine in the European Union (EU) in Over a Decade for Chronic Spontaneous Urticaria (CSU)
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
AI Revolutionizes Drug Shelf-Life: Optimized Stability Models Promise Safer, More Effective Medicines
Via TokenRing AI
Topics Artificial Intelligence Economy Product Recall
News headline image
Biopharma Boom: M&A Frenzy, AI Revolution, and GLP-1 Gold Rush Drive Robust Growth in 2025
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Why Roche Holding Stock Popped Today ↗
Via The Motley Fool
News headline image
TG Therapeutics Crumbles After Roche Unveils Its 'Unprecedented' Test Results ↗
Via Investor's Business Daily
News headline image
Merck Takes On Amgen, Regeneron, Lowering Stubbornly High Cholesterol By 60% ↗
Via Investor's Business Daily
News headline image
AI Achieves Atomic Precision in Antibody Design: A New Era for Drug Discovery Dawns
Via TokenRing AI
Topics Artificial Intelligence Intellectual Property
News headline image
AI Unleashes a New Era in Cell and Gene Therapy: A Quarter Century Update Reveals Transformative Potential
Via TokenRing AI
Topics Artificial Intelligence

Frequently Asked Questions

Is Sanofi - American Depositary Shares publicly traded?
Yes, Sanofi - American Depositary Shares is publicly traded.
What exchange does Sanofi - American Depositary Shares trade on?
Sanofi - American Depositary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Sanofi - American Depositary Shares?
The ticker symbol for Sanofi - American Depositary Shares is SNY on the Nasdaq Stock Market
What is the current price of Sanofi - American Depositary Shares?
The current price of Sanofi - American Depositary Shares is 48.74
When was Sanofi - American Depositary Shares last traded?
The last trade of Sanofi - American Depositary Shares was at 12/30/25 04:00 PM ET
What is the market capitalization of Sanofi - American Depositary Shares?
The market capitalization of Sanofi - American Depositary Shares is 60.96B
How many shares of Sanofi - American Depositary Shares are outstanding?
Sanofi - American Depositary Shares has 61B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.